"Imipenem" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.
| Descriptor ID |
D015378
|
| MeSH Number(s) |
D02.065.589.099.124.300.500 D03.633.100.300.124.300.500
|
| Concept/Terms |
Imipenem- Imipenem
- N-Formimidoylthienamycin
- N Formimidoylthienamycin
- Imipemide
|
Below are MeSH descriptors whose meaning is more general than "Imipenem".
Below are MeSH descriptors whose meaning is more specific than "Imipenem".
This graph shows the total number of publications written about "Imipenem" by people in this website by year, and whether "Imipenem" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 2 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2016 | 0 | 2 | 2 |
| 2017 | 7 | 6 | 13 |
| 2018 | 5 | 7 | 12 |
| 2019 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Imipenem" by people in Profiles.
-
Drug repurposing of anti-infective clinical drugs: Discovery of two potential anti-cytokine storm agents. Biomed Pharmacother. 2020 Nov; 131:110643.
-
Antimicrobial susceptibilities of the ertapenem-non-susceptible non-carbapenemase-producing Enterobacterales isolates causing intra-abdominal infections in the Asia-Pacific region during 2008-2014: Results from the Study for Monitoring the Antimicrobial Resistance Trends (SMART). J Glob Antimicrob Resist. 2020 06; 21:91-98.
-
Protein expression profiles in methicillin-resistant Staphylococcus aureus (MRSA) under effects of subminimal inhibitory concentrations of imipenem. FEMS Microbiol Lett. 2019 08 01; 366(15).
-
Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J. 2019 07; 54(1).
-
In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan. J Antimicrob Chemother. 2019 02 01; 74(2):380-386.
-
An improved carbapenem inactivation method, CIMTrisII, for carbapenemase production by Gram-negative pathogens. J Med Microbiol. 2019 Feb; 68(2):124-131.
-
Daptomycin as adjunctive treatment for experimental infection by Acinetobacter baumannii with resistance to colistin. Int J Antimicrob Agents. 2019 Feb; 53(2):190-194.
-
Carbapenem susceptibilities of Gram-negative pathogens in intra-abdominal and urinary tract infections: updated report of SMART 2015 in China. BMC Infect Dis. 2018 Sep 29; 18(1):493.
-
In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli. Antimicrob Agents Chemother. 2018 08; 62(8).
-
Clonal Background, Resistance Gene Profile, and Porin Gene Mutations Modulate In Vitro Susceptibility to Imipenem-Relebactam in Diverse Enterobacteriaceae. Antimicrob Agents Chemother. 2018 08; 62(8).